EHA 2021 | DARIA: second-line dara plus ixazomib and dex in len-refractory myeloma patients
Evangelos Terpos, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, gives an update on the Phase II DARIA study (NCT03746652) which is exploring the efficacy of daratumumab (dara) in combination with ixazomib and dexamethasone (dex) as second-line therapy in patients with relapsed/refractory (R/R) multiple myeloma who have been treated with a prior lenalidomide (len)-based regimen. Daratumumab is an anti-CD38 monoclonal antibody. Prof. Terpos outlines data from 40 patients, 70% of whom are lenalidomide-refractory and 38% of whom had received prior autologous transplantation. The response rate was 57.5% with a median time from first dose to first response of one month. The median progression-free survival was 10.4 months. Prof. Terpos discusses these results, as well as giving an overview of the safety findings. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Evangelos Terpos, MD, PhD, has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Genesis Pharmaceuticals, Janssen-Cilag, Novartis, Sanofi and Takeda; has participated in a consulting or advisory role for Amgen, Celgene, Genesis Pharmaceuticals, Janssen-Cilag, Sanofi and Takeda; has received research funding from Amgen, Genesis Pharmaceuticals, Janssen-Cilag, Sanofi and Takeda, and has received travel, accommodation or expenses from Amgen, Genesis Pharmaceuticals, Janssen-Cilag and Takeda.
